Home Home  
Contact Us
About TRA
Our Mission
Staff & Physicians
Career Opportunities
News
Exam Info
Exam Safety
FAQ
Results Info
New Technology
Source Library
 



New Technology
Positron Emission Tomography (PET)

 

Medicare approved indications for PET

Breast Cancer

Initial staging, re-staging
Medicare-approved effective October 1, 2002

Single Pulmonary Nodule

Characterization of malignant potential in nodule less than 4 cm

Lung Cancer

Non Small Cell Diagnosis, staging, re-staging

Esophageal Cancer

Diagnosis, staging, re-staging

Colorectal Cancer

Diagnosis, staging, re-staging

Lymphoma

Diagnosis, staging, re-staging

Melanoma

Diagnosis, staging, re-staging; not covered for regional lymph node evaluation

Head + Neck Cancers

Diagnosis, staging, re-staging; not covered for CNS and thyroid cancer

Myocardial Viability

Metabolic assessment for myocardial viability following inconclusive SPECT

Refractory Seizures

Metabolic brain imaging for pre-surgical evaluation refractory seizures

Appropriate Indications for PET — not covered by Medicare:

  • Thyroid Carcinoma
  • Carcinoma of the Cervix
  • Differentiation of Recurrent Brain Tumor form Radiation Necrosis
  • Alzheimer's Disease
  • Seizures

Return to top


Overview

Positron emission tomography (PET) uses radioactive glucose to evaluate the metabolic activity of organs and disease processes. Unlike CT, MRI or ultrasound, which evaluate anatomy, PET evaluates function, how much glucose is being utilized.

Most cancers are far more metabolically active than the surrounding tissue and will have increased utilization of glucose, which allows for detection with a PET scanner. Some diseases, such as Alzheimer's disease, have decreased metabolic activity compared to normal. This is also detected with a PET scan.

The radioactive glucose that is injected accumulates throughout the body, allowing for the entire body to be scanned during a single exam. PET may eventually replace multiple imaging modalities in the work up of certain diseases, such as cancer. Being a relatively new technique, Medicare and insurance coverage for PET is limited to the indications listed.


Return to top


What patients need to know

PET (positron emission tomography) is a powerful diagnostic tool that, in many cases, renders answers that no other imaging test can provide. Biochemical changes caused by certain diseases are detected by the PET scanner after an IV injection of a trace amount of FDG-18, a radioactive, sugar like substance. The body's distribution of this "tracer" is mapped by the PET scanner. Reactions to FDG-18 are extremely rare. PET scans are considered to be quite safe.

Although PET exams are similar experientially to a CT scan (patient lies on a table which moves slowly through a doughnut shaped gantry), PET is fundamentally different than CT, x-ray or MRI in that PET produces an image of metabolism. X-ray, CT and MRI are useful in producing images or structure or anatomy.

Dietary and exercise preparation for a PET scan and length examination depend on the information needed. In general, patients should allow for a couple of hours to complete the exam. On time arrival for a PET exam is extremely important as FDG-18 is individually prepared (titrated) for timed administration. Unless patient the patient is given medication to reduce anxiety, they should not feel any different than how they did prior to the scan.


Return to top



Imaging technology

  • ADAC Allegro PET Scanner

Return to top


Available at

 

TRA Medical Imaging — Tacoma
2202 S Cedar Street, Stuite 200
Tacoma, WA 98405

Roy McCulloch, CNMT
Supervisor PET and Nuclear Medicine

(253) 284-0616

Scheduling and clinic

(253) 761-4200

Scheduling fax

(253) 761-4201

Medical records fax

(253) 284-0622



TRA clinical PET specialists: